The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.

礼来是全球最有价值的医疗保健股票，市值超过8000亿美元。在过去12个月里，股价上涨了超过50%。尽管增长前景强劲，但投资者可能会对该股超过100倍的市盈率感到犹豫。

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...